Baseline demographic and clinical characteristics, circulating endothelial cells, plasma levels of VWF and IL-6 in acute coronary syndrome, stable coronary artery disease, and healthy control subjects
. | Acute coronary syndrome, n = 156 . | Stable CAD, n = 36 . | Control subjects, n = 40 . |
---|---|---|---|
Age, y, mean ± SD | 65 ± 12 | 60 ± 12 | 60 ± 8 |
Male, n (%) | 110 (71) | 26 (72) | 27 (68) |
BMI, kg/m2, mean ± SD | 27 ± 4 | 27 ± 4 | 28 ± 5 |
Active smoker, n (%) | 54 (35) | 5 (13) | 4 (10) |
Systolic BP, mm Hg, mean ± SD | 131 ± 18 | 136 ± 23 | 135 ± 16 |
Cholesterol, mmol/L, mean ± SD | 5.7 ± 0.9 | 3.6 ± 0.7 | 5.6 ± 0.7 |
HDL-C, mmol/L, mean ± SD | 1.0 ± 0.1 | 1.3 ± 0.2 | 1.4 ± 0.1 |
Creatinine, μmol/L, mean ± SD | 89 ± 23 | 88 ± 17 | 79 ± 17 |
Glucose, mmol/L, mean ± SD | 7.4 ± 2.9 | 6.2 ± 2.6 | 5.0 ± 0.7 |
Research indexes | |||
VWF, IU/dL, mean ± SD | 215 ± 59 | 147 ± 32 | 121 ± 20 |
IL-6, pg/mL, median (IQR) | 27.2 (12.8-61.7) | 13.4 (8.2-27.7) | 10.4 (6.9-14.7) |
CECs, cells/mL, median (IQR) | 10.63 (5.75-14.5) | 3.13 (2.25-4.0) | 2.75 (1.56-3.94) |
. | Acute coronary syndrome, n = 156 . | Stable CAD, n = 36 . | Control subjects, n = 40 . |
---|---|---|---|
Age, y, mean ± SD | 65 ± 12 | 60 ± 12 | 60 ± 8 |
Male, n (%) | 110 (71) | 26 (72) | 27 (68) |
BMI, kg/m2, mean ± SD | 27 ± 4 | 27 ± 4 | 28 ± 5 |
Active smoker, n (%) | 54 (35) | 5 (13) | 4 (10) |
Systolic BP, mm Hg, mean ± SD | 131 ± 18 | 136 ± 23 | 135 ± 16 |
Cholesterol, mmol/L, mean ± SD | 5.7 ± 0.9 | 3.6 ± 0.7 | 5.6 ± 0.7 |
HDL-C, mmol/L, mean ± SD | 1.0 ± 0.1 | 1.3 ± 0.2 | 1.4 ± 0.1 |
Creatinine, μmol/L, mean ± SD | 89 ± 23 | 88 ± 17 | 79 ± 17 |
Glucose, mmol/L, mean ± SD | 7.4 ± 2.9 | 6.2 ± 2.6 | 5.0 ± 0.7 |
Research indexes | |||
VWF, IU/dL, mean ± SD | 215 ± 59 | 147 ± 32 | 121 ± 20 |
IL-6, pg/mL, median (IQR) | 27.2 (12.8-61.7) | 13.4 (8.2-27.7) | 10.4 (6.9-14.7) |
CECs, cells/mL, median (IQR) | 10.63 (5.75-14.5) | 3.13 (2.25-4.0) | 2.75 (1.56-3.94) |
BMI indicates body mass index; HDL-C, high density lipoprotein cholesterol; CAD, coronary artery disease; VWF, von Willebrand factor; IL-6, interleukin-6; CEC, circulating endothelial cells.